Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Australian Healthcare Herald.
Press releases published on July 28, 2025
EIN Presswire Debuts Podcast with PR Insider Sherrie Handrinos on the Power of Influencer Marketing
EIN Presswire
·
July 28, 2025
“Heard on the Streets” podcast explores how brands are cashing in on social media strategy WASHINGTON , DC, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- EIN Presswire has launched its first audio podcast on Substack, and it’s diving into one of …
K10 Vision's Powerful New Release Features Groundbreaking AI Integration
EIN Presswire
·
July 28, 2025
K10 Vision Lays the Groundwork for the Transformational Role to be Played by Audit Management Software in the Months and Years Ahead LEEDS, UNITED KINGDOM, July 28, 2025 /EINPresswire.com/ -- K10 Vision is delighted to announce the launch of the latest …
USPTO Grants Patent for Novel Therapeutics for Antibody-Cannabinoid Conjugates
EIN Presswire
·
July 28, 2025
Diverse Biotech Emerging as Leader in Cannabinoid Drug Conjugate Space With Landmark Patent MIAMI, FL, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- Diverse Biotech Inc., an innovative developer in novel drug technology, today announced a pivotal …
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
GlobeNewswire
·
July 28, 2025
Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25 SYDNEY, July 28, 2025 (GLOBE NEWSWIRE) -- Radiopharm …
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
GlobeNewswire
·
July 28, 2025
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ATH434 was Well-Tolerated with Favorable Safety Profile – …